Long-Term Epoprostenol Therapy in Pulmonary Artery Hypertension - Sequence of Changes in Hemodynamic Effects

被引:5
|
作者
Sakuma, Masahito [1 ]
Demachi, Jun [2 ]
Nawata, Jun [3 ]
Suzuki, Jun [4 ]
Takahashi, Tohru [5 ]
Shirato, Kunio [6 ]
机构
[1] Onagawa Municipal Hosp, Div Internal Med, Washinokamihama, Onagawa, Japan
[2] Ishinomaki Municipal Hosp, Ishinomaki, Miyagi, Japan
[3] Nakajima Hosp, Div Internal Med, Sendai, Miyagi, Japan
[4] Kurihara Cent Hosp, Dept Internal Med, Kurihara, Japan
[5] Iwate Cent Prefectural Hosp, Dept Cardiol, Morioka, Iwate, Japan
[6] Saito Hosp, Div Internal Med, Ishinomaki, Miyagi, Japan
关键词
Cardiac index; Pulmonary artery pressure; Pulmonary vascular selectivity; Total pulmonary resistance; PROSTACYCLIN; SURVIVAL; INFUSION;
D O I
10.1253/circj.CJ-07-1020
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Sequential changes in the hemodynamic effect of chronic epoprostenol therapy raise the following questions. Does an increase in cardiac Output (CO) precede lowering of the pulmonary artery pressure (PAP) over the time course of improvement? What are the characteristics of good responders to chronic epoprostenol treatment? Methods and Results: Hemodynamics were evaluated by catheter examination. Most patients still alive after >1 year showed an increase in CO either with no change in mean PAP or accompanied by a decrease in mean PAP during increased dosing of epoprostenol. Immediately before cessation of the increase in epoprostenol dose in good responders, the ratio of total pulmonary resistance to total systemic resistance was low, and the pulmonary artery wedge pressure minus right atrial pressure was high compared with the newest data in poor responders. One year after fixing at the best dose of epoprostenol, the mean PAP further decreased. Conclusions: In good responders, pulmonary selectivity to epoprostenol is high, and the blood returning to the left-sided heart through the pulmonary circulation increases. Hemodynamics further improve, even after fixing at the best dose of epoprostenol. The present data did not show that an increase in CO precedes lowering of the PAP over the course of improvement. (Circ J 2009; 73: 523-529)
引用
收藏
页码:523 / 529
页数:7
相关论文
共 50 条
  • [1] LONG-TERM OUTCOMES OF EPOPROSTENOL THERAPY IN SARCOID ASSOCIATED PULMONARY HYPERTENSION
    Abston, Erie
    Moll, Matthew
    Hon, Stephanie
    Govender, Praveen
    Berman, Jeffrey
    Farber, Harrison
    SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES, 2020, 37 (02) : 184 - 191
  • [2] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Calcaianu, Mihaela
    Canuet, Matthieu
    Enache, Irina
    Kessler, Romain
    PULMONARY CIRCULATION, 2017, 7 (02) : 439 - 447
  • [3] Withdrawal of long-term epoprostenol therapy in pulmonary arterial hypertension (PAH)
    Calcaianu, George
    Chaouat, Ari
    Canuet, Matthieu
    Kessler, Romain
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [4] Successful withdrawal of long-term epoprostenol therapy for pulmonary arterial hypertension
    Kim, NH
    Channick, RN
    Rubin, LJ
    CHEST, 2003, 124 (04) : 1612 - 1615
  • [5] Long-term Effects of Epoprostenol on the Pulmonary Vasculature in Idiopathic Pulmonary Arterial Hypertension
    Rich, Stuart
    Pogoriler, Jennifer
    Husain, Aliya N.
    Toth, Peter T.
    Gomberg-Maitland, Mardi
    Archer, Stephen L.
    CHEST, 2010, 138 (05) : 1234 - 1239
  • [6] Long-Term Pulmonary Hemodynamic Effects of Ambrisentan in Pulmonary Arterial Hypertension
    Klinger, James R.
    Oudiz, Ronald J.
    Spence, Rebecca
    Despain, Darrin
    Dufton, Christopher
    AMERICAN JOURNAL OF CARDIOLOGY, 2011, 108 (02): : 302 - 307
  • [7] Reduction in pulmonary vascular resistance with long-term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension
    McLaughlin, VV
    Genthner, DE
    Panella, MM
    Rich, S
    NEW ENGLAND JOURNAL OF MEDICINE, 1998, 338 (05): : 273 - 277
  • [8] Cutaneous findings in patients with pulmonary arterial hypertension receiving long-term epoprostenol therapy
    Myers, SA
    Ahearn, GS
    Selim, MA
    Tapson, VE
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (01) : 98 - 102
  • [9] Long-term oxygen therapy in patients with pulmonary artery hypertension
    Subba, Sristina
    Johnshon, Saumy
    Devasia, Tom
    INDIAN JOURNAL OF RESPIRATORY CARE, 2019, 8 (01) : 31 - 35
  • [10] Twin pregnancy in a woman on long-term epoprostenol therapy for primary pulmonary hypertension -: A case report
    Badalian, SS
    Silverman, RK
    Aubry, RH
    Longo, J
    JOURNAL OF REPRODUCTIVE MEDICINE, 2000, 45 (02) : 149 - 152